Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Nuffield Department of Clinical Neurosciences (NDCN) have begun a clinical trial to assess whether the drug sildenafil could improve blood flow to the brain.

Model of a human brain © Robina Weermeijer, Unsplash

University of Oxford researchers have begun a clinical trial to assess whether the drug sildenafil, more commonly known by its commercial name Viagra, could improve blood flow to the brain and so have the potential to reduce damage to small blood vessels in the brain and prevent strokes.

Chronic damage to small blood vessels deep in the brain is found in half of patients over the age of 60 and almost all patients over the age of 80, and is responsible for up to a third of strokes and around 40 percent of dementia.​

Dr Alastair Webb, of the Wolfson Centre for Prevention of Stroke and Dementia (NDCN), based at the John Radcliffe Hospital, is leading the study. He explained: “There is limited evidence for how this small vessel disease develops and no specific treatment.”

“We aim to test whether sildenafil has the potential to reduce small vessel damage.”

Potential explanations for how small vessel disease develops include: a greater change in blood pressure with each beat of the heart (pulsatility), which hits the brain with increased force with each beat; or a reduced ability of the blood vessels in the brain to adapt to changes in the environment, also known as their reactivity.

Read more (Nuffield Department of Clinical Neurosciences website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.